Secretory glycoproteins begin their life in the endoplasmic reticulum (ER). In the ER environment, nascent polypeptides undergo co-translational signal peptide cleavage and N-linked glycosylation, disulfide bonds are formed and the proteins acquire their mature tertiary and quaternary structures. A number of resident molecular chaperones and enzymes help the maturation processes: for example, the ER molecular chaperones BiP, Grp94, calnexin and calreticulin bind to nascent polypeptides and increase their efficiency of folding and assembly; the ER enzyme protein disulfide isomerase (PDI) catalyses the formation of intrachain and interchain disulfide bridges.
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To ensure that only structurally mature and properly assembled proteins are allowed to reach their final destination -secretion, the plasma membrane or subcompartments of the secretory pathway -the ER employs a number of 'quality control' mechanisms [1] . These mechanisms monitor the folding and oligomerisation state of secretory proteins, and provide further assistance to polypeptides that have not yet achieved their correct structure. Quality control allows only correctly folded and assembled proteins to leave the ER; immature, permanently misfolded or unassembled proteins are retained in the ER and eventually degraded. Recent studies have shed new light on the role of oligosaccharide processing in targeting for degradation glycoproteins that, for one reason or another, fail to mature properly [2, 3] .
The best known example of a quality control mechanism operating in the ER on newly synthesized glycoproteins is the calnexin-calreticulin cycle [4] . N-linked oligosaccharides are attached to newly synthesized proteins in the ER (Figure 1 ). The oligosaccharides undergo rapid trimming of two of the three glucose residues by ER glucosidases I and II. Calnexin and calreticulin are lectin chaperones which, acting in a complex with the lumenal oxidoreductase Erp57 [5] , bind to monoglucosylated glycoproteins and promote their folding. The proteins are then released and their remaining glucose residue is removed by glucosidase II. If the proteins are correctly folded, they are permitted to leave the ER. If, however, folding is incomplete, the glycoproteins are recognised by the enzyme UDP-glucose:glycoprotein glucosyltransferase (UGT), which re-glucosylates their oligosaccharides, allowing the proteins to undergo a new cycle of calnexin binding. UGT therefore functions as a real folding sensor, by determining which proteins are structurally sound and which ones require further rounds of interaction with calnexin. 
It seems that, in the ER, every protein is given a good chance to mature properly. In some cases, nevertheless, a protein can fail to mature. Proteins that are terminally misfolded, as a result of mutation, cellular stress [6] or viral infection [7] , or unassembled subunits of multimeric proteins, such as the T-cell receptor [8, 9] , are singled out by the quality control system and retained inside the ER, mostly by interactions with chaperones, and eventually targeted for degradation. In recent years, the nature of this degradation process, commonly referred to as ER-associated degradation (ERAD), has been the subject of intense investigation. It is now accepted that the cytosolic 26S proteasome is the ultimate site of degradation of ER-located defective proteins or orphan protein subunits [10] . There is evidence, both in yeast and mammalian cells, that condemned proteins are dislocated from the ER to the cytosol through the Sec61 translocon and degraded by the proteasome. Once in the cytosol, proteins can be deglycosylated and/or ubiquitinated prior to proteasomal disposal.
Although the proteasome is the most popular destination for ERAD substrates, recent reports suggest that cytoplasmic disposal might not be the only route of degradation for defective proteins. Degradation of partially folded human glycoprotein thyroperoxidase, for example, seems to be dependent on cysteine and serine proteases associated with the ER membrane [11] . Similarly, the regulated turnover of wild-type, non-glycosylated membrane proteins, such as HMG-coenzyme A reductase and stearoyl-coenzyme A desaturase, appears also to depend on ER membraneassociated proteases [12, 13] . Furthermore, there is evidence that proteases in the ER lumen might be involved in degradation of human P-glycoprotein [14] . Much work is needed to elucidate further these alternative proteolytic pathways.
How are misfolded glycoproteins recognised as such and targeted for ERAD? Recent evidence indicates that the structure of the N-linked glycans, resulting from the action of various glycosidases resident in the ER (Figure 1) , can influence the efficiency of targeting of glycoproteins to proteolysis in the cytoplasm [15, 16] . This suggests that there is some form of conformational sensing of proteinbound sugars, and this is likely to involve the lectin chaperones, such as calnexin and calreticulin, and the ER oligosaccharide-processing enzymes. In particular, a number of recent reports seem to suggest a key role for the ER mannosidases.
De Virgilio et al. [17] recently showed that a truncated form of the ribophorin -an ERAD substrate -in which glycosylation sites were removed was degraded in vivo with faster kinetics than the glycosylated form. An analogous effect was observed when glycosylated ribophorin was synthesised in the presence of castanospermine, a drug that inhibits glucose trimming ( Figure 1 ) and therefore prevents binding to calnexin. This suggests that A model for the integration of the calnexin cycle, glycan trimming and disposal routes in the quality control of glycoproteins (modified from [1] association with calnexin retards degradation. Treatment with inhibitors of ER mannosidases, such as 1-deoxymannojirimycin, greatly stabilised ribophorin, suggesting that mannose trimming is required for degradation [17] .
Similarly, treatment with castanospermine resulted in faster degradation of class I major histocompatibility complex (MHC) heavy chains in a mammalian semipermeabilised cell system [2] . The same effect was also observed with semi-permeabilised cells from a mutant cell line lacking calnexin, again suggesting that calnexin interaction prolongs the lifetime of a misfolded protein. Treatment with either castanospermine or 1-deoxymannojirimycin inhibited degradation, showing that mannose trimming of the glycan is the crucial step required to target MHC class I heavy chains for proteolysis, independently of calnexin binding [2] . Reduced degradation on inhibition of ER mannosidase activity has also been observed for other mammalian ERAD substrates, such as unassembled CD3 δ subunits of the T cell receptor [9] and misfolded α 1 -antitrypsin [16] , and for carboxypeptidase Y in mannosidase-deficient yeast strains [15] .
The emerging picture from all this evidence is that mannose trimming is sufficient to regulate the half-life and the ultimate fate of glycoproteins in the ER (Figure 2 ). An alternative interpretation, based on studies with α 1 -antitrypsin, is that the number of mannose residues on the oligosaccharide chain affects the efficiency of binding and release from calnexin: when the glycan is in the GlcNAc 2 Man 8 Glc 1 form -a poor substrate for glucosidase II -dissociation from calnexin is retarded and the prolonged interaction with calnexin per se could sequester the glycoprotein from the folding pathway and target it for degradation [16] .
In their recent paper, Cabral et al. [3] provide additional evidence to support this controversial interpretation. Several defective variants of α 1 -antitrypsin are targeted by the proteasome after prolonged interaction with calnexin. But Cabral et al. [3] found that the PI Z variant of α 1 -antitrypsin is degraded in vivo by a process that does not involve the proteasome. Degradation of PI Z could be blocked by inhibitors of tyrosine phosphatase activity, such as sodium pervanadate. It appears that PI Z is a substrate for the non-proteasomal proteolytic pathway only when its glycan has been processed to the GlcNAc 2 Man 7 form, which is no longer a suitable substrate for calnexin binding. When cells are treated with inhibitors of the ER mannosidases, such as kifunensine or swainsonine, so that PI Z is locked into the calnexin cycle, the protein is degraded by the proteasome and its degradation can be inhibited by the proteasome-specific inhibitor lactacystin, as previously shown for other α 1 -antitrypsin variants [16] .
When castanospermine was added post-translationally, once again locking PI Z in the calnexin cycle, degradation was similarly performed by the proteasome [3] . But when castanospermine was added co-translationally, thus inhibiting all glucose removal and preventing PI Z from binding calnexin at all, the protein was found to be degraded by the non-proteasomal pathway [3] . Simultaneous use of castanospermine and 1-deoxymannojirimycin, as in the experiments of Wilson et al. [2] , would be required to determine whether calnexin binding is really needed to target PI Z for proteasomal degradation. Nevertheless, the data reported by Cabral et al. [3] indicate that, in the case of PI Z, mannose trimming of the oligosaccharide chain, whilst still acting as a regulator for calnexin binding, also plays a role in sorting PI Z to different degradative pathways. Identifying the nature of the non-proteasomal degradation pathway will be an exciting goal for future work.
